PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study
NCT07387861
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
OTHER:
Not applicable- observational study
Sponsor
Assiut University